Severe Acute Respiratory Syndrome Coronavirus 2 serosurveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demography and healthcare setting

Hughes, E. C. et al. (2021) Severe Acute Respiratory Syndrome Coronavirus 2 serosurveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demography and healthcare setting. Journal of Infectious Diseases, 223(6), pp. 971-980. (doi: 10.1093/infdis/jiaa788) (PMID:33367847) (PMCID:PMC7798933)

[img] Text
227349.pdf - Published Version
Available under License Creative Commons Attribution.

4MB

Abstract

Identifying drivers of SARS-CoV-2 exposure and quantifying population immunity is crucial to prepare for future epidemics. We performed a serial cross-sectional serosurvey throughout the first pandemic wave among patients from the largest health board in Scotland. Screening of 7480 patient sera showed a weekly seroprevalence ranging from 0.10% to 8.23% in primary and 0.21% to 17.44% in secondary care, respectively. Neutralisation assays showed that around half of individuals who tested positive by ELISA assay, developed highly neutralising antibodies, mainly among secondary care patients. We estimated the individual probability of SARS-CoV-2 exposure and quantified associated risk factors. We show that secondary care patients, males and 45-64-year-olds exhibit a higher probability of being seropositive. The identification of risk factors and the differences in virus neutralisation activity between patient populations provided insights into the patterns of virus exposure during the first pandemic wave and shed light on what to expect in future waves.

Item Type:Articles
Keywords:SARS-CoV-2, COVID-19, virus exposure, serology, virus neutralisation, modelling, risk factors, seroprevalence.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Willett, Professor Brian and Amat, Mr Julien and Arthur, Ms Ursula and Herbert, Miss Imogen and Viana, Dr Mafalda and Nickbakhsh, Dr Sema and Szemiel, Dr Agnieszka and Gunson, Dr Rory and Hughes, Ellen and Broos, Ms Alice and Haney, Miss Joanne and Ho, Dr Antonia and Parr, Ms Yasmin and Logan, Miss Nicola and Murcia, Professor Pablo
Authors: Hughes, E. C., Amat, J. A.R., Haney, J., Parr, Y. A., Logan, N., Palmateer, N., Nickbakhsh, S., Ho, A., Cherepanov, P., Rosa, A., McAuley, A., Broos, A., Herbert, I., Arthur, U., Szemiel, A. M., Roustan, C., Dickson, E., Gunson, R. N., Viana, M., Willett, B. J., and Murcia, P. R.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
College of Medical Veterinary and Life Sciences > School of Veterinary Medicine
Journal Name:Journal of Infectious Diseases
Publisher:Oxford University Press
ISSN:0022-1899
ISSN (Online):1537-6613
Published Online:26 December 2020
Copyright Holders:Copyright © 2020 The Authors
First Published:First published in Journal of Infectious Diseases 223(6):971–980
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
172630Quinquennial Core FundsMassimo PalmariniMedical Research Council (MRC)MC_UU_12014/9III-MRC-GU CVR Support Services
307106Epidemiology meets biotechnology: preventing viral emergence from batsDaniel StreickerWellcome Trust (WELLCOTR)217221/Z/19/ZInstitute of Biodiversity, Animal Health and Comparative Medicine
301313Atypical bovine morbillivirus infections in the Serengeti ecosystemBrian WillettBiotechnology and Biological Sciences Research Council (BBSRC)BB/R004250/1III - Centre for Virus Research
302172A One Health approach to pan-valent morbillivirus vaccinesBrian WillettBiotechnology and Biological Sciences Research Council (BBSRC)BB/R019843/1III - Centre for Virus Research